Is Tau How? GMS Bets $31.5M on Alzheimer's Phase III Effort
By Randy Osborne
Wednesday, November 21, 2012
After years of throwing themselves futilely against the beta amyloid wall, companies trying for Alzheimer's disease (AD) therapies are turning away, hoping to find a door that opens on a way to modify the devastating condition.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.